Cabazitaxel clinical trials
Also written Jevtana, XRP6258 and RPR-116258A.
How each study uses cabazitaxel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the cabazitaxel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 17 Jun 2010 · JEVTANA KIT · NDA 201023 (FDA, Drugs@FDA)
- European Union
- 17 Mar 2011 · Jevtana · EMEA/H/C/002018 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
88 studies that test it; most in 2012 (18)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 9 |
| 2012 | 18 |
| 2013 | 14 |
| 2014 | 9 |
| 2015 | 7 |
| 2016 | 2 |
| 2017 | 9 |
| 2018 | 3 |
| 2019 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 21 · Other 68
Sanofi (19) · M.D. Anderson Cancer Center (4) · University Hospitals Bristol and Weston NHS Foundation Trust (3) · UNICANCER (2) · Gustave Roussy, Cancer Campus, Grand Paris (2) · Sidney Kimmel Cancer Center at Thomas Jefferson University (2) · Vejle Hospital (2) · Hellenic Cooperative Oncology Group (2)
Often tested with
Tested in the same studies.
Carboplatin (8) · Prednisone (8) · Abiraterone (6) · Enzalutamide (5) · Abiraterone Acetate (4) · Lutetium (¹⁷⁷Lu) vipivotide tetraxetan (3) · Docetaxel (3) · Nivolumab (2)
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 4 phase 3 studies under way
Cabazitaxel is the comparator. A study of two new drugs counts under both.
- 2Xaluritamig · Amgen · next primary completion Jan 2029
- 2Darolutamide · ECOG-ACRIN Cancer Research Group, Karolinska Institutet · next primary completion Dec 2026
- 1Enzalutamide · Karolinska Institutet · next primary completion Dec 2026
- 1Abiraterone · Karolinska Institutet · next primary completion Dec 2026
- 1Carboplatin · Karolinska Institutet · next primary completion Dec 2026
- 1Docetaxel · Karolinska Institutet · next primary completion Dec 2026
- 1Niraparib · Karolinska Institutet · next primary completion Dec 2026
- 1Abiraterone Acetate · Karolinska Institutet · next primary completion Dec 2026
Reaching primary completion within a year · 3
Studies that test cabazitaxel.
- Nov 2026Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)Phase 2 · Fundacion Oncosur
- Dec 2026A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate CancerPhase 2 · Jina Pharmaceuticals Inc.
- Sep 2027Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)Phase 1/2 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses cabazitaxel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 89
- Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT06632977Written as Cabazitaxel
- Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate CancerRecruitingPhase 2Case Comprehensive Cancer CenterNCT06738303Written as Cabazitaxel and carboplatin
- Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06085729Written as Cabazitaxel
- A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate CancerNot yet recruitingPhase 2Jina Pharmaceuticals Inc.NCT06890832Written as 50 mg cabazitaxel
- Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)RecruitingPhase 2Fundacion OncosurNCT05563558Written as Cabazitaxel
- Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical OutcomeNot yet recruitingPhase 2The Clatterbridge Cancer Centre NHS Foundation TrustNCT04622761Written as Cabazitaxel
- Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With DocetaxelActive, not recruitingPhase 2ECOG-ACRIN Cancer Research GroupNCT03419234Written as Cabazitaxel
- Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate CancerActive, not recruitingPhase 1/2OHSU Knight Cancer InstituteNCT02522715Written as Cabazitaxel
- Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast CancerCompletedPhase 2University Hospitals Bristol and Weston NHS Foundation TrustNCT03048942Written as Cabazitaxel
- Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPCCompletedPhase 2M.D. Anderson Cancer CenterNCT03263650Written as Cabazitaxel
- CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and AbirateroneCompletedPhase 2Masonic Cancer Center, University of MinnesotaNCT03934840Written as Cabazitaxel
- A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate CancerActive, not recruitingPhase 2Andrew J. Armstrong, MDNCT04709276Written as Cabazitaxel
- A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell TumorsCompletedPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT02115165Written as Cabazitaxel
- Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate CancerCompletedPhase 3Gustave Roussy, Cancer Campus, Grand ParisNCT02044354Written as Jevtana
- Bristol Bladder TrialCompletedPhase 2University Hospitals Bristol and Weston NHS Foundation TrustNCT01616875Written as Cabazitaxel + Cisplatin chemotherapy
- A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)CompletedPhase 2Bristol-Myers SquibbNCT02985957Written as Cabazitaxel
- A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of RelapseActive, not recruitingPhase 3UNICANCERNCT01952223Written as Cabazitaxel
- Cabazitaxel With Radiation and Hormone Therapy for Prostate CancerCompletedPhase 1Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT01420250Written as Cabazitaxel
- Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based ChemotherapyCompletedPhase 2Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT01437488Written as Cabazitaxel
- Docetaxel Versus Cabazitaxel Post Abiraterone or EnzalutamideTerminatedPhase 2Centre hospitalier de l'Université de Montréal (CHUM)NCT03764540Written as Cabazitaxel plus prednisone
See all 89 studies that test cabazitaxel →
Given beside what is tested · 18 — cabazitaxel is usual care or a partner of the new treatment
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerRecruitingPhase 1Janssen Research & Development, LLCNCT05818683Written as Cabazitaxel
- AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)RecruitingPhase 3AstraZenecaNCT07611110Written as Cabazitaxel
- Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the BodyRecruitingPhase 3SWOG Cancer Research NetworkNCT06470243Written as Cabazitaxel
- Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)Active, not recruitingPhase 1/2Merck Sharp & Dohme LLCNCT06353386Written as Cabazitaxel
- Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT02703623Written as Cabazitaxel
- Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT04592237Written as Cabazitaxel
- XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate CancerCompletedPhase 2Xencor, Inc.NCT05005728Written as vudalimab + carboplatin + cabazitaxel
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedPhase 1OHSU Knight Cancer InstituteNCT03878524Written as Cabazitaxel
- A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.CompletedPhase 2AstraZenecaNCT04495179Written as Cabazitaxel
- Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate CancerTerminatedPhase 1/2Medical University of South CarolinaNCT01335204Written as Cabazitaxel plus bavituximab
- Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate CancerCompletedPhase 4SanofiNCT02441894Written as CABAZITAXEL XRP6258
- Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate CancerCompletedPhase 3Achieve Life SciencesNCT01578655Written as cabazitaxel
- A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)TerminatedPhase 3Achieve Life SciencesNCT01083615Written as cabazitaxel
- Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid TumorsCompletedPhase 1Merrimack PharmaceuticalsNCT01447225Written as Cabazitaxel
- Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate CancerCompletedPhase 1/2SanofiNCT01511536Written as Cabazitaxel XRP6258
- Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate CancerCompletedPhase 4SanofiNCT02074137Written as CABAZITAXEL XRP6258
- Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With DocetaxelWithdrawnPhase 2SCRI Development Innovations, LLCNCT02035124Written as Cabazitaxel
- Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSATerminatedPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT01531205Written as Cabazitaxel
As the comparator · 7 — what is tested is compared with cabazitaxel
- A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerRecruitingPhase 3AmgenNCT07213674Written as Cabazitaxel
- Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate CancerNot yet recruitingPhase 2/3ECOG-ACRIN Cancer Research GroupNCT07852195Written as Cabazitaxel
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerRecruitingPhase 3Karolinska InstitutetNCT03903835Written as Cabazitaxel 60 mg Solution for Injection
- Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)Active, not recruitingPhase 3AmgenNCT06691984Written as Cabazitaxel
- A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate CancerCompletedPhase 2Australian and New Zealand Urogenital and Prostate Cancer Trials GroupNCT03392428Written as Cabazitaxel
- Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells KineticCompletedPhase 2UNICANCERNCT03101046Written as Cabazitaxel
- A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate CancerCompletedPhase 2Jeffrey Yachnin M.D., PhD.NCT01541007Written as Cabazitaxel
Codes
What other systems call cabazitaxel · ClinicalTrials.gg INT005712
- MeSH (NLM) C552428cabazitaxelConfirmed NLM, Wikidata
- UNII (FDA) 51F690397JCABAZITAXELConfirmed FDA, NLM, Wikidata
- RxNorm 996051Confirmed FDA, Wikidata
- Wikidata Q412963cabazitaxelConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66937CabazitaxelOne source FDA
- DrugBank DB06772One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C552428 | cabazitaxel | Confirmed NLM, Wikidata |
| UNII (FDA) | 51F690397J | CABAZITAXEL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 996051 | — | Confirmed FDA, Wikidata |
| Wikidata | Q412963 | cabazitaxel | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66937 | Cabazitaxel | One source FDA |
| DrugBank | DB06772 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.